Magenta therapeutics reports second quarter financial results and recent program highlights

– mgta-117 phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tolerability profile; interim clinical data disclosure anticipated in q4 2022 –

DNTH Ratings Summary

DNTH Quant Ranking